WCN26-953 Finerenone in Proteinuria Management Among Diabetic Kidney Disease Patients: Real-World Data from Central India

Read full text Summarise with VIRAT
Authors: Sushrut Gupta, Sunny Malde, Twinkle Pawar, Vijay Jeyachandran, Mohit M. Kurundwadkar, Kapil Navin Sejpal, Prasad Gurjar, Charulata P Bawankule, Amit S Pasari, Manish Ramesh Balwani
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist. Activation of MR on cells in the distal nephron, podocytes, fibroblasts, vascular cells, and macrophages plays a key role in driving inflammation, tubular injury, and fibrosis progression in the kidneys of patients with diabetic nephropathy (DN). Finerenone has demonstrated the ability to slow the decline in kidney function and reduce the incidence of kidney failure or kidney disease-related death. It is also associated with a reduced risk of adverse cardiovascular outcomes.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Renal Diseases and Glomerulopathies Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104583–104583
Publication date
25 March 2026
Language
EN